A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/23/2006	CA2608309A1 Substituted spiro compounds and their use for producing pain-relief medicaments
11/23/2006	CA2608273A1 Aerosolized fluoroquinolones and uses thereof
11/23/2006	CA2608240A1 Multicyclic compounds and methods of their use
11/23/2006	CA2608214A1 Quinoline derivatives as ep4 antagonists
11/23/2006	CA2608189A1 Low dose administration of a topical composition
11/23/2006	CA2608185A1 Oral medicament based on a proton pump inhibitors
11/23/2006	CA2608016A1 Improving bone formation and preservation by surgically inducing an increase in osteoblast activity coupled with the effect of administering pthrp or cgrp
11/23/2006	CA2608014A1 Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
11/23/2006	CA2608012A1 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
11/23/2006	CA2608010A1 Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
11/23/2006	CA2608009A1 Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
11/23/2006	CA2607883A1 Pyrrolobenzodiazepines and heteroaryl, aryl and cycloalkylamino ketone derivatives as follicle stimulating hormone receptor (fsh-r) antagonists
11/23/2006	CA2607882A1 Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (fsh-r) antagonists
11/23/2006	CA2607726A1 Method of treating lymphangioleiomyomatosis (lam)
11/23/2006	CA2607472A1 Antipyretic agents against vr1-antagonist-induced increases in body temperature
11/23/2006	CA2607326A1 Diarylsulfone sulfonamides and use therof
11/23/2006	CA2607325A1 The use of rapamycin derivatives for the treatment and/or prevention of cardiovascular disorders
11/23/2006	CA2607299A1 Compounds and compositions as protein kinase inhibitors
11/23/2006	CA2607291A1 Compositions and methods for modulating immune responses
11/23/2006	CA2606994A1 Hypoallergenic flavor compositions and methods of managing allergic reactions in pets
11/23/2006	CA2606785A1 Fibroblast activation protein inhibitor compounds and methods
11/23/2006	CA2606769A1 Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors
11/23/2006	CA2606583A1 Aldehyde conjugated flavonoid preparations
11/23/2006	CA2606567A1 Use of adamantyl methoxydiphenyl propenoic acid for the treatment of acne
11/23/2006	CA2606017A1 Tyrosine kinase inhibitors
11/23/2006	CA2605508A1 Blockade of pin1 prevents cytokine production by activated immune cells
11/23/2006	CA2605337A1 Crystal polymorph of hydroxynorephedrin derivative hydrochloride
11/23/2006	CA2605272A1 Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
11/23/2006	CA2605050A1 Histone deacetylase inhibitors
11/23/2006	CA2604568A1 Sustained release l-arginine formulations and methods of manufacture and use
11/23/2006	CA2604562A1 Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2)
11/23/2006	CA2604452A1 Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject
11/23/2006	CA2600689A1 Method for determining phytase activity
11/23/2006	CA2558202A1 Vitamin d compositions and method of administration to infants
11/22/2006	EP1724353A2 Methods of forming protein-linked lipidic microparticles
11/22/2006	EP1724351A2 Human Kallikrein-like genes
11/22/2006	EP1724350A1 Method and compositions for the diagnosis and treatment of cancer
11/22/2006	EP1724339A1 Gene regulation therapy involving ferritin
11/22/2006	EP1724287A1 Hyaluronic acid/methotrexate compound
11/22/2006	EP1724286A1 Variant CD44 polypeptide, polynucleotides encoding same, antibodies directed there against and method of using same for diagnosing and treating inflammatory diseases
11/22/2006	EP1724279A2 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia.
11/22/2006	EP1724278A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
11/22/2006	EP1724277A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
11/22/2006	EP1724271A1 Preventive and/or therapeutic agent for neutrophilic inflammation disease
11/22/2006	EP1724270A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
11/22/2006	EP1724269A1 Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
11/22/2006	EP1724268A1 Compound having tgf-beta inhibitory activity and pharmaceutical composition containing same
11/22/2006	EP1724267A1 Pyrimidine derivative
11/22/2006	EP1724265A1 Anticancer agent
11/22/2006	EP1724264A1 Nitriles and medicinal compositions containing the same as the active ingredient
11/22/2006	EP1724263A1 Basic amine compound and use thereof
11/22/2006	EP1724262A1 1-(2h)-isoquinolone derivative
11/22/2006	EP1724259A1 2,7-substituted 5-amino-4-hydroxy-8-(1h-indazol-5-yl)-octan amide derivatives and related compounds as renin inhibitors for the treatment of hypertension
11/22/2006	EP1724258A1 Heteroarylphenylurea derivative
11/22/2006	EP1724257A1 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
11/22/2006	EP1723970A1 Medicinal composition containing cxcr3 inhibitor
11/22/2006	EP1723968A1 Erythrocyte function modifying substance
11/22/2006	EP1723967A2 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
11/22/2006	EP1723964A1 Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections
11/22/2006	EP1723958A2 dsRNA vectorisation with cationic particles and their topical use
11/22/2006	EP1723957A2 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
11/22/2006	EP1723956A1 Preventive or therapeutic agents for severe diabetic retinopathy
11/22/2006	EP1723955A1 Medicine for prevention and/or treatment of ischemic circulatory disease
11/22/2006	EP1723954A1 Indazole derivatives for the treatment of cancer
11/22/2006	EP1723953A1 Nutritional supplements
11/22/2006	EP1723952A1 Antiwrinkling preparation
11/22/2006	EP1723951A1 Nutritional supplement with oligosaccharides for a category of HIV patients
11/22/2006	EP1723950A2 Method of treating dopaminergic gaba-nergic disorders
11/22/2006	EP1723948A1 Controlled release compositions of biguanide with less side effects and treatment regimen thereof
11/22/2006	EP1723246A1 New expression tools for multiprotein applications
11/22/2006	EP1723234A1 Vglut-specific dsrna compounds
11/22/2006	EP1723231A1 A small synthetic rna, a method of preparing the same and uses thereof
11/22/2006	EP1723227A2 Nicotinamide riboside kinase compositions and methods for using the same
11/22/2006	EP1723165A1 Identification of n-alkylglycine trimers for induction of apoptosis
11/22/2006	EP1723164A1 BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS
11/22/2006	EP1723158A2 O,o -amidomalonate and n,o-amidomalonate platinum complexes
11/22/2006	EP1723157A1 Amorphous forms of risedronate monosodium
11/22/2006	EP1723152A1 Pyrrolobenzodiazepines
11/22/2006	EP1723151A2 Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines
11/22/2006	EP1723150A1 Rifamycin imino derivatives effective against drug-resistant microbes
11/22/2006	EP1723148A2 Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors
11/22/2006	EP1723147A1 Process for inhibiting cell proliferation
11/22/2006	EP1723146A1 Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
11/22/2006	EP1723145A2 Substituted 5,12-diaza-benzoanthracene analogues
11/22/2006	EP1723144A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
11/22/2006	EP1723142A1 Diphenylmethyl compounds useful as muscarinic receptor antagonists
11/22/2006	EP1723139A1 Cell targeting conjugates
11/22/2006	EP1723138A1 Substituted benzimidazoles and their use for inducing apoptosis
11/22/2006	EP1723137A1 Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives
11/22/2006	EP1723136A1 Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
11/22/2006	EP1723134A2 Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
11/22/2006	EP1723132A1 Ep2 receptor agonists
11/22/2006	EP1723131A1 Crystalline polymorphs of a cxc-chemokine receptor ligand
11/22/2006	EP1723129A1 1-akan-2-ol substituted piperazine and piperidine compounds
11/22/2006	EP1723128A1 Heteroaryl-ureas and their use as glucokinase activators
11/22/2006	EP1723127A2 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
11/22/2006	EP1723126A2 Novel mch receptor antagonists
11/22/2006	EP1723125A1 Novel 1,2,4-benzotriazine-1,4-dioxides
11/22/2006	EP1723122A2 Dimeric small molecule potentiators of apoptosis
11/22/2006	EP1723121A1 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors

1 ... 3997 3998 3999 4000 4001 4002 4003 4004 4005 4006 4007 4008 4009 4010 4011 4012 4013 4014 4015 4016 4017 ... 7860